WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will take center stage at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina, with a late-breaking oral presentation on its Phase 3 clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel. The event, running from April 8 to April 11, 2025, provides a global platform for innovative research in pediatric dermatology.
The presentation will spotlight the findings of SELVA, a 24-week, single-arm, baseline-controlled trial evaluating the efficacy and safety of the gel for treating microcystic lymphatic malformations in individuals aged three and older. These rare and often debilitating vascular anomalies present a significant unmet need within the field of dermatology, making the trial’s results a key discussion point at the congress.
The abstract, titled “SELVA: A Phase 3 study with a fit-for-purpose primary endpoint evaluating QTORIN™ 3.9% rapamycin anhydrous gel in the treatment of microcystic lymphatic malformations in patients 3 years of age and older,” will be delivered by Dr. Amy Paller. Dr. Paller is a highly regarded expert in dermatology, holding multiple academic roles, including the Walter J. Hamlin Professor and Chair of Dermatology at Northwestern University’s Feinberg School of Medicine. She also serves as Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center.
The session is scheduled for Friday, April 11, 2025, between 8:30 and 10 a.m. local time in Room F during the “Free Communications VII” segment, which focuses on clinical and epidemiological studies.
Palvella Therapeutics’ participation aims to foster collaboration and conversation within the medical community about this novel therapeutic approach.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.